Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer

This trial is testing a combination of three drugs — irinotecan liposomes, cetuximab, and vemurafenib — as second-line treatment for advanced colorectal cancer. The combination is designed specifically for tumors with a BRAF V600E mutation or RAS wild-type status that have progressed after first-line chemotherapy. **You may be eligible if...** - You are 18 or older - You have colorectal cancer confirmed by biopsy with either RAS wild-type or BRAF V600E mutation - Your cancer has progressed after or you could not tolerate standard first-line treatment - You have at least one measurable tumor on imaging - You are in good general health (ECOG 0–2) - Your blood counts and organ function are adequate **You may NOT be eligible if...** - You have not tried first-line standard chemotherapy - Your blood counts or organ function do not meet study requirements - Your cancer has specific genetic profiles not covered by this treatment combination Talk to your doctor to see if this trial is right for you.